EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council



Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council



Seminars in Oncology 29(1): 97-101



Malignant mesothelioma is almost invariably fatal. The incidence of the disease is rising rapidly in many countries, and there is no generally accepted standard treatment for patients with unresectable disease. According to current British Thoracic Society (BTS) guidelines, patients should be treated with active symptom control (ASC), involving (1) regular follow-up in a specialist clinic; (2) structured assessments of physical, psychological and social problems with appropriate action; (3) rapid involvement of additional specialists; and (4) parallel nursing support. Although many nonrandomized studies have reported tumor responses to anticancer chemotherapy, few have studied palliation and it is not known whether chemotherapy prolongs survival or provides clinically worthwhile palliation with acceptable toxicity when given in addition to ASC. We therefore plan to conduct a multicenter randomized controlled trial comparing (1) ASC alone, (2) ASC plus mitomycin vinblastine and cisplatin (MVP), and (3) ASC plus vinorelbine (N; Navelbine, Pierre Fabre Oncology, Winchester, UK). We chose these chemotherapy regimens because they have been shown in nonrandomized studies to provide good symptom control as recorded by patients. The outcome measures are overall survival, palliation of symptoms, performance status, analgesic usage, toxicity, quality of life, tumor response, and recurrence/progression-free survival. In a preliminary feasibility study, we are assessing the acceptability of the trial design to patients and the suitability of two standard quality-of-life instruments in mesothelioma. Data will help us to decide the final details of the large multicenter trial.

(PDF same-day service: $19.90)

Accession: 035349903

Download citation: RISBibTeXText

PMID: 11836674

DOI: 10.1053/sonc.2002.30235



Related references

The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. The British Thoracic Society Research Committee and the Medical Research Council Cardiothoracic Epidemiology Group. Respiratory Medicine 85(4): 319-323, 1991

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. Journal of Clinical Oncology 18(2): 395-404, 2000

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73(Suppl 1): I1-I30, 2018

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73(Suppl 1): I1-I30, 2018

British Thoracic Society randomized feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma. British Journal of Cancer 86(Supplement 1): S62, June, 2002

Commentary: the 1944 patulin trial: the first properly controlled multicentre trial conducted under the aegis of the British Medical Research Council. International Journal of Epidemiology 33(2): 253-260, 2004

Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. Journal of Clinical Oncology 23(33): 8371-8379, 2005

British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 52(1): 38-44, 1997

Update on progress in the international, multicenter, randomized, controlled trial of corticosteroids after significant head injury (Medical Research Council CRASH Trial). Current Opinion in Critical Care 9(2): 92-97, 2003

Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. British Thoracic Society Research Committee. British Medical Journal 290(6475): 1106-1108, 1985

Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). Journal of Antimicrobial ChemoTherapy 70(2): 325-359, 2015

Preliminary results of the Hong Kong/British Medical Research Council second controlled trial of short-course antituberculosis regimens. Tubercle 59(1): 64-64, 1978

Smoking cessation in patients: two further studies by the British Thoracic Society. Research Committee of the British Thoracic Society. Thorax 45(11): 835-840, 1990

Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study. American Review of Respiratory Disease 131(5): 727-731, 1985

Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council. Tubercle 54(2): 99-129, 1973